Immuno Oncology Assays Market is Forecasted to Value Over US $ 6 Billion by 2026 End

  • 21 Aug 2019

Immuno Oncology Assays Market to value over US $ 6 Billion and register a CAGR of over 12% during the forecast period from 2019 to 2026.

Rising exposure to carcinogenic agents and a subsequent rise in the number of cancer cases and casualties is surging the demand for effective treatment will further boost industry growth during the forecast timeline. Continuous research for novel cancer treatment is projected to foster immuno oncology assays market growth. The significant factors contributing to the growth of the global immuno oncology assays market are increasing incidences of cancer and rising adoption of targeted therapy over traditional therapy. However, unfavourable regulatory and reimbursement scenario and high capital investment amount might hinder the overall market at a global level.

Based on indication, the immuno-oncology assays market is segmented into lung cancer, colorectal cancer, melanoma, bladder cancer, and other cancers. The lung cancer segment is projected to be the fastest-growing segment during the forecast period, as major firms are focusing on immuno-oncology research for lung cancer owing to its increasing incidence.

Based on products, the immuno-oncology assays market is segmented into consumables and software. The consumables segment garnered the major immuno oncology assays market share and is also expected to register the highest CAGR during the forecast period. The availability of variety, increasing use of reagents in various oncology therapeutic treatments, continuous research on cancer immunotherapy is fueling the growth of this segment.

Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics. Research applications held significant market share and are projected to grow with a robust CAGR value during the forecast period. The increasing significance of biomarker-based drug development and clinical trials and the awareness of cancer immunotherapy are the principal factors driving immuno oncology assays market growth.

According to the region, North America held major revenue in the global immuno oncology assays market. This is accredited to the increasing cancer cases, the advanced healthcare infrastructure, and rising adoption of targeted therapy. Continued research with the favourable scenario for capital funding also boosts the immuno oncology assays market growth.

The Asia Pacific immuno oncology assays market will thrive at the highest CAGR in the projected time frame owing to the rising geriatric population, increasing cancer cases, and augmenting health awareness.

Prominent Players operating in the global immuno-oncology assays industry are Thermo Fisher Scientific (US), Roche Diagnostics (Switzerland), Agilent Technologies (US), and Illumina (US).

Competitive Landscape

● Thermo Fisher entered into a deal with Invivoscribe Technologies to develop NGS-based in-vitro diagnostic oncology tests in order to strengthen their position in the global market

● Illumina launched its TruSight Oncology 500 assay, which is used to identify known and emerging tumour biomarkers, this expanded the product portfolio and explored the potential of the market

Immuno Oncology Assays Market Segmentation

By Product

● Consumables

● Software

By Technology 


● Immunoassay

● Ngs

● Flow Cytometry

● Other Technologies

By Indication 

● Lung Cancer

● Colorectal Cancer

● Melanoma

● Bladder Cancer

● Other Cancers

By Application 

● Research Applications

● Clinical Diagnostics

By Region

● Europe

● North America


● Latin America

● Rest of World

Competitive Landscape: 

● Tier 1 players- established companies in the market with a major market share

● Tier 2 players

● Emerging players which are growing rapidly

● New Entrants 

FutureWise Takeaways 

● Growth prospects

● SWOT analysis

● Key trends

● Key data points affecting market growth

Objectives of the Study:

● To provide an exhaustive analysis on the global immuno oncology assays market by product, by technology, by indication by application, and by region

● To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)

● To evaluate and forecast micro-markets and the overall market

● To predict the market size, in key regions (along with countries)—North America, Europe, Asia Pacific, Latin America, and the rest of the world

● To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

● Profiling of companies to evaluate their market shares, strategies, financials and core competencies


Get unlimited analyst support and customise this study further to your requirements, contact